Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 15/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036305 | 0.92 | ORAI1 (0.55) | ORAI1METAP2ULK1GCGR | |
| SCHEMBL15020468 | 0.80 | ORAI1 (0.59) | ORAI1ULK1 | |
| SCHEMBL15020539 | 0.78 | ORAI1 (0.62) | ORAI1ULK1 | |
| SCHEMBL15750874 | 0.74 | ORAI1 (0.61) | ORAI1ULK1 | |
| SCHEMBL15751300 | 0.70 | ORAI1 (0.86) | ORAI1ULK1 | |
| SCHEMBL15020464 | 0.66 | ORAI1 (0.59) | ORAI1ULK1 | |
| SCHEMBL15750813 | 0.64 | ORAI1 (1.00) | ORAI1ULK1 | |
| SCHEMBL15751035 | 0.64 | ORAI1 (0.73) | ORAI1ULK1 | |
| SCHEMBL15033682 | 0.63 | METAP2 (0.46) | METAP2CNR1 | |
| SCHEMBL23775421 | 0.63 | ATM (0.41) | ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158690-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K11, MAP3K13, WEE2 | ORAI1 4481/4885METAP2 1263/4885ULK1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.